Process for producing coenzyme q10

TECHNICAL FIELD

[0001] The present invention relates to a process for producing coenzyme Q10, which is in use as a drug or the like. More particularly, it relates to a process for causing formation of coenzyme Q10 by isolating a gene coding for a coenzyme Q10 side chain synthase, which serves as a key enzyme in the biosynthesis of coenzyme Q10, namely a decaprenyl diphosphate synthase, from a fungal species belonging to the genus Bulleromyces and introducing that gene into a microorganism.

BACKGROUND ART

[0002] An industrial process for producing coenzyme Q10, which is conventional in the art, comprises, for example, isolating coenzymes of plant origin, for example of tobacco origin, and adjusting the side chain length thereof by a synthetic method.

[0003] It is known that coenzyme Q10 is produced in a wide variety of organisms, from microorganisms, such as bacteria and yeasts, to higher animals and plants. Thus, the process comprising cultivating a microorganism and extracting this substance from cells thereof can be regarded as one of the most efficient processes for producing coenzyme Q10 and has actually been employed in commercial production thereof. However, the productivity of such processes can hardly be said to be good, since the productivity is low and the procedure is complicated, for instance.

[0004] Attempts have also been made to increase the production of coenzyme Q10 by isolating genes involved in the biosynthesis of coenzyme Q10 and amplifying the genes utilizing the recombinant DNA technology. Coenzyme Q10 is formed in vivo in a multistage process comprising complicated reactions in which a number of enzymes are involved. The route of biosynthesis thereof in prokaryotes partially differs from that in eukaryotes. Basically, however, each route comprises three fundamental steps, namely the step of synthesis of decaprenyl diphosphate, which is the source of the prenyl side chain of coenzyme Q10, the step of synthesis of para-hydroxybenzoic acid, which is the source of the quinone ring, and the step of completion of coenzyme Q10 through coupling of these two compounds and successive substituent conversions. Among these reactions, the reaction which determines the side chain length of coenzyme Q10, namely the decaprenyl diphosphate synthase-involving reaction, which is said to be a rate-determining one in the whole biosynthetic reaction route, is considered to be the most important one.

[0005] Therefore, for efficient production of coenzyme Q10, it is considered effective to isolate a decaprenyl diphosphate synthase gene, which is the key gene in the biosynthesis of coenzyme Q10, and utilize the same for the purpose of increasing production. As for the gene source, fungi, in which coenzyme Q10 is produced in relatively large amounts, are leading candidates.

[0006] So far, decaprenyl diphosphate synthase genes have been isolated from several microorganisms, such as Schizosaccharomyces pombe (JP-A-09-173076) and Gluconobacter suboxydans (JP-A-10-57072). However, the productivity of coenzyme Q10 in these microorganisms cannot be said to be satisfactory, and the cultivation of these microorganisms and the separation/purification of coenzyme Q10 therefrom have not been efficient. It has thus been desired that a microorganism-derived gene for that enzyme, which enables high level production of coenzyme Q10, be isolated. As regards fungus-derived decaprenyl diphosphate synthase genes, the isolation of such a gene from a microorganism belonging to the genus Saitoella has been reported (WO 00/5659). However, there is no report available about the isolation of such an enzyme gene from a microorganism belonging to the genus Bulleromyces.

SUMMARY OF THE INVENTION

[0007] It is an object of the present invention to produce coenzyme Q10 efficiently in microorganisms by isolating a coenzyme Q10 side chain synthesis gene from a fungal species belonging to the genus Bulleromyces and utilizing the same to thereby solve the above-mentioned productivity problem.

[0008] For attaining the above object, in the present inventioin, firstly, investigations were made in an attempt to isolate a key gene involved in the biosynthesis of coenzyme Q10, a decaprenyl diphosphate synthase gene from fungi belonging to the genus Bulleromyces and, as a result, succeeded in isolating such gene. This success has now led to completion of the present invention.

[0009] Thus, the present invention relates to

[0010] a DNA of the following (a), (b) or (c):

[0011] (a) a DNA whose base sequence is as described under SEQ ID NO:1;

[0012] (b) a DNA having a base sequence derived from the base sequence shown under SEQ ID NO:1 by deletion, addition, insertion and/or substitution of one or several bases and

[0013] encoding a protein having decaprenyl diphosphate synthase activity;

[0014] (c) a DNA capable of hybridizing with a DNA comprising the base sequence shown under SEQ ID NO:1 under a stringent condition and

[0015] encoding a protein having decaprenyl diphosphate synthase activity.

[0016] The invention further relates to

[0017] a protein of the following (d) or (e):

[0018] (d) a protein whose amino acid sequence is as described under SEQ ID NO:2;

[0019] (e) a protein having an amino acid sequence derived from the amino acid sequence shown under SEQ ID NO:2 by deletion, addition, insertion and/or substitution of one or several amino acid residues and having decaprenyl diphosphate synthase activity.

[0020] The invention further relates to

[0021] DNAs respectively encoding the proteins (d) or (e).

[0022] Furthermore, the invention relates to

[0023] an expression vector resulting from insertion of the DNA mentioned above into a vector for expression,

[0024] the above expression vector,

[0025] in which the vector for expression is pUCNT, and

[0026] the above expression vector,

[0027] which is pNTB1.

[0028] The invention further relates to

[0029] a transformant resulting from transformation of a host microorganism with the DNA mentioned above,

[0030] a transformant resulting from transformation of a host microorganism with the above expression vector,

[0031] the above transformant,

[0032] wherein the host microorganism is Escherichia coli,

[0033] the above transformant,

[0034] wherein the Escherichia coli is Escherichia coli DH5α, and

[0035] the above transformant,

[0036] which is Escherichia coli DH5α (pNTB1)(FRPM BP-7512).

[0037] The invention still further relates to

[0038] a process for producing coenzyme Q10,

[0039] which comprises cultivating the transformant in a medium and recovering coenzyme Q10 thus formed and accumulated in the medium.

DETAILED DISCLOSURE OF THE INVENTION

[0040] The present inventors made investigations to isolate a gene encoding the enzyme in question from fungi belonging to the genus Bulleromyces, in which coenzyme Q10 is produced in relatively large amounts, and, as a result, succeeded in obtaining a fragment of the gene by PCR method.

[0041] First, the sequence of a known gene encoding a decaprenyl diphosphate synthase was compared with that of a known gene encoding a polyprenyl diphosphate synthase which is an analogue of the enzyme in question and a long prenyl chain synthase of different chain length coenzyme Q, and various PCR primers were synthesized for regions showing high homology therebetween. PCR conditions were studied for various combinations of these primers and, as a result, it was revealed, by gene base sequence analysis, that when 40 PCR cycles, each comprising 94° C., 1 minute→43° C., 2 minutes→72° C., 2 minutes, are carried out after 3 minutes of heat treatment at 94° C., using the primers DPS-1 (SEQ ID NO:3 in the sequence listing) and DPS-1 1AS (SEQ ID NO:4 in the sequence listing), a fragment, about 220 bp in size, of the enzyme gene in question is amplified from the chromosomal gene of Bulleromyces albus IFO 1192, which is a fungal species belonging to the genus Bulleromyces.

[0042] Then, for obtaining the enzyme gene in its full length, mRNA was prepared from cells of Bulleromyces albus IFO 1192, a 5′ terminal side fragment of that enzyme gene was obtained by preparing a primer based on the inner sequence previously obtained and utilizing the 5′RACE method, and a 3′ terminal side fragment was obtained by conducting RT-PCR using oligo dT primer relative to a poly A sequence, which is specific for the mRNA. Further, primers were prepared based on the inner sequences of the respective fragments obtained, and PCR was conducted using them, whereby a DNA fragment supposedly comprising the full-length enzyme gene in question was obtained.

[0043] The base sequence of the DNA fragment obtained was determined, whereupon it was revealed that it has the sequence shown under SEQ ID NO:1 in the sequence listing. In the amino acid sequence predicted from this base sequence, there was found a sequence characteristic of decaprenyl diphosphate synthase gene.

[0044] The DNA of the present invention may be a DNA whose base sequence is as described under SEQ ID NO:1, or a DNA having a base sequence derived from the base sequence shown under SEQ ID NO:1 by deletion, addition, insertion and/or substitution of one or several bases and encoding a protein having decaprenyl diphosphate synthase activity, or a DNA capable of hybridizing with a DNA comprising the base sequence shown under SEQ ID NO:1 under a stringent condition and encoding a protein having decaprenyl diphosphate synthase activity.

[0045] A number of amino acids each may be encoded by one or more codons (genetic code degeneracy), so that a number of DNAs other than the DNA having the base sequence shown under SEQ ID NO:1 can encode the protein having the amino acid sequence shown under SEQ ID NO:2. Therefore, the DNA of the invention includes such DNAs encoding the protein having the amino acid sequence shown under SEQ ID NO:2 as well.

[0046] The expression “the base sequence derived by deletion, addition, insertion and/or substitution of one or several bases” as used herein means a base sequence resulting from deletion, addition, insertion and/or substitution of such a number of bases as can be deleted, added, inserted and/or substituted according to the methods well known to those skilled in the art, for example those as described in Supplemental Issue, Tanpakushitsu, Kakusan, Koso (Protein, Nucleic Acid and Enzyme), PCR Method for Gene Amplification, TAKKAJ, 35 (17), 2951-3178 (1990) or Henry A. Erlich (ed.), translated into Japanese under the supervision of Ikunoshin Kato: PCR Technology (1990).

[0047] The expression “DNA capable of hybridizing with a DNA comprising the base sequence shown under SEQ ID NO:1 under a stringent condition” means a DNA obtainable by utilizing the technique of colony hybridization, plaque hybridization or southern hybridization, among others, using a DNA comprising the base sequence shown under SEQ ID NO:1 as a probe. Those skilled in the art would be able to readily obtain the desired DNA by carrying out such hybridization according to the method described in Molecular Cloning, 2nd Edt. (Cold Spring Harbor Laboratory Press, 1989). For example, the desired DNA can be obtained by carrying out such hybridization at a temperature of 50° C. or above and at a salt concentration of urea-free SSC of not higher than 0.5 M.

[0048] The expression “protein having decaprenyl diphosphate synthase activity” means a protein capable of synthesizing decaprenyl diphosphate in a yield of not less than 10%, preferably not less than 40%, more preferably not less than 60%, still more preferably not less than 80%, as compared with the case where a protein having the amino acid sequence shown under SEQ ID NO:2 is used. Such capacity can be measured by reacting FPP (farnesyl diphosphate) with 14C-IPP (radiolabeled isopentenyl diphosphate) in the presence of the enzyme in question, hydrolyzing the resulting 14C-DPP (decaprenyl diphosphate) with phosphatase and, after separation by TLC, determining the incorporation in each spot for each chain length (Okada et al., Eur. J. Biochem., 255, 52-59).

[0049] The protein of the invention may be a protein whose amino acid sequence is as described under SEQ ID NO:2, or a protein having an amino acid sequence derived from the amino acid sequence shown under SEQ ID NO:2 by deletion, addition, insertion and/or substitution of one or several amino acid residues and having decaprenyl diphosphate synthase activity.

[0050] Such “an amino acid sequence derived by deletion, addition, insertion and/or substitution of one or several amino acid residues” can be obtained by deleting, adding, inserting and/or substituting such a number of amino acid residues as can be deleted, added, inserted and/or substituted by site-directed mutagenesis or any other methods well known in the art. Such methods are specifically described, for example, in Nucleic Acids Res., 10, 6487 (1982) and Methods in Enzymology, 100, 448 (1983).

[0051] For causing expression of the decaprenyl diphosphate synthase gene, it is necessary to connect that gene to a site downstream of an appropriate promoter. It is possible to construct an expression vector, for example, by excising a DNA fragment containing the gene using a restriction enzyme or amplifying an enzyme-encoding gene portion alone by PCR and then inserting the fragment or amplification product into a promoter-containing vector.

[0052] In the practice of the invention, the vector in which a DNA encoding a protein having decaprenyl diphosphate synthase activity is to be inserted to give an expression vector is not particularly restricted but may be one derived from an Escherichia coli-derived plasmid with an appropriate promoter inserted therein. The Escherichia coli-derived plasmid includes, among others, pBR322, pBR325, pUC19, pUC18, and pUC119. The promoter includes, among others, the T7 promoter, trp promoter, tac promoter, lac promoter, and λPL promoter.

[0053] In the practice of the invention, pGEX-2T, pGEX-3T, pGEX-3X (the three being products of Pharmacia), pBluescriptII, pUC19, pUC18 (product of Toyobo Co., Ltd.), pMALC2, pET-3T, pUCNT (described in WO 94/03613) and the like may also be used as vectors for expression. Among these, pUCNT is suitably used. In a specific example, a decaprenyl diphosphate synthase gene expression vector can be constructed by inserting a gene having the base sequence shown under SEQ ID NO:1 into the vector for expression pUCNT.

[0054] And, by introducing the above DNA or expression vector into an appropriate host microorganism, it becomes possible to utilize the microorganism for the production of coenzyme Q10. In other words, the DNA or expression vector can be utilized in the production of coenzyme Q10 in the form of a transformant produced by transforming a host microorganism therewith.

[0055] The host microorganism is not particularly restricted but Escherichia coli and the like are suitably used. The Escherichia coli strain is not particularly restricted but includes XL1-Blue, BL-21, JM109, NM522, DH5α, HB101, and DH5, among others. Among them, Escherichia coli DH5α is suitably used. For example, when a decaprenyl diphosphate synthase gene expression vector pNTB1 is introduced into Escherichia coli, this can be transformed so that coenzyme Q10, which Escherichia coli originally does not produce, can be produced. This Escherichia coli strain E. coli DH5α(pNTB1) has been internationally deposited as of Mar. 16, 2001, under the Budapest Treaty, with the National Institute of Advanced Industrial Science and Technology International Patent Organism Depositary, Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan, under the accession number FERM BP-7512.

[0056] Coenzyme Q10 can be produced by cultivating the transformant obtained in the present invention in a medium in the conventional manner and recovering coenzyme Q10 from the cultivation product.

[0057] In cases where the host microorganism is Escherichia coli, LB medium, or M9 medium containing glucose and casamino acids, for instance, can be used as the medium. For better promoter functioning, such an agent as isopropylthiogalactoside or indolyl-3-acrylic acid, for instance, may be added to the medium. The cultivation is carried out, for example, at 20 to 40° C., preferably 30 to 37° C., more preferably 37° C., for 17 to 24 hours, if necessary with aeration and/or agitation.

[0058] In the practice of the invention, the product coenzyme Q10 obtained may be purified or used in the form of a crude product according to the selection duly made depending on the intended use thereof. Coenzyme Q10 can be isolated from the cultivation product by an appropriate combination of per se known methods of separation and/or purification. The per se known methods of separation and/or purification include salting out, solvent precipitation and other methods utilizing the difference in solubility; dialysis, ultrafiltration, gel filtration, (SDS-) polyacrylamide gel electrophoresis and other methods mainly utilizing the difference in molecular weight; ion exchange chromatography and other methods utilizing the difference in charge; affinity chromatography and other methods utilizing specific affinity; reversed phase high-performance liquid chromatography and other methods utilizing the difference in hydrophobicity; isoelectric focusing and other methods utilizing the difference in isoelectric point, among others.

[0059] The field of utilization of coenzyme Q10 obtained in the present invention is not particularly restricted but it may be suitably used as a drug, among others.

BRIEF DESCRIPTION OF THE DRAWINGS

[0060]
FIG. 1 is a restriction enzyme map of the expression vector pNTB1.

[0061]
FIG. 2 shows HPLC analysis charts showing production of coenzyme Q10 by recombinant E. coli DH5α (pNTB1).

BEST MODES FOR CARRYING OUT THE INVENTION

[0062] The following examples illustrate the present invention in more detail. These examples are, however, by no means limitative of the scope of the invention.

EXAMPLE 1

[0063] The chromosomal DNA of Bulleromyces albus IFO 1192 was prepared by the method of C. S. Hoffman et al. (Gene, 57 (1987), 267-272). Based on the homology with the known long-chain prenyl diphosphate synthase gene, primers for use in PCR, namely DPS-1 (SEQ ID NO:3 in the sequence listing) and DPS-1 1AS (SEQ ID NO:4 in the sequence listing), were designed. Using these, a PCR cycle of 94° C., 1 minute→43° C., 2 minutes→72° C., 2 minutes, was repeated 40 times after 3 minutes of heat treatment at 94° C., followed by 1.2% agarose gel electrophoresis.

[0064] The thus-obtained fragment, about 220 bp in size, was purified by excising the corresponding gel portion from the gel and then treating it with a DNA extraction kit (Sephaglas (trademark) BrandPrep Kit, product of Amersham Pharmacia Biotech), and the purified fragment was cloned into a vector for expression in Escherichia coli using a PCR product direct cloning kit (pT7 BlueT-Vector Kit, product of NOVAGEN) to give pT7-B1DPS. The DNA base sequence was determined by carrying out the reaction on a DNA sequencer (model 377, product of Perkin Elmer) using a DNA sequencing kit (product of Perkin Elmer, ABI PRISM (trademark) BigDye (trademark) Terminator Cycle Sequence Ready Reaction Kit with AmptiTaq (registered trademark) DNA polymerase, FS) and according to the manual attached thereto. As a result, a DNA fragment having a base sequence covering the 835th to 1,044th bases of the base sequence shown under SEQ ID NO:1 in the sequence listing were obtained from Bulleromyces albus IFO 1192. These DNA fragments were estimated to be part of the decaprenyl diphosphate synthase gene since the amino acid sequence “GDFLLXRA” (X is A or G), which is a characteristic region of the long-chain prenyl chain-containing prenyl diphosphate synthase, could be found in the sequence translated from the base sequence determined in the above manner.

EXAMPLE 2

[0065]

Bulleromyces albus
IFO 1192 was cultured in 50 mL of 703 medium (5 g/L pepton, 3 g/L yeast extract, 3 g/L malt extract, and 1 g/L glucose, pH 6.0) for 48 hours at 25° C. Then, the cells were harvested by centrifugation at 3,000 revolutions for 20 minutes and frozen immediately in liquid nitrogen.

[0066] The frozen cells were placed in a mortar chilled previously at −70° C. and ground to a powder with a pestle while being kept frozen by occasionally adding liquid nitrogen. Total RNA was prepared from the well-powdered cells using an RNeasy Maxi RNA Purification Kit (product of Qiagen K.K.). Total RNA thus extracted was further purified using an RNeasy Mini RNA Purification Kit (product of Qiagen K.K.). From the purified total RNA, mRNA was prepared using an mRNA purification kit (Ologotex-dT30 <Super> (trademark) mRNA Purification kit, product of Takara Shuzo Co., Ltd.).

EXAMPLE 3

[0067] The DNA fragment containing the region from the DNA obtained in Example 1 to the 3′-terminal region of the decaprenyl diphosphate synthase gene of Bulleromyces albus IFO 1192 was obtained. RT-PCR was carried out using an RT-PCR kit (High fidelity RNA PCR Kit, product of Takara Shuzo Co., Ltd.) and primer B1S (SEQ ID NO:5 in the sequence listing) which was generated based on the inner sequence of the DNA fragment obtained in Example 1.

[0068] The thus-obtained fragment, about 850 bp in size, was purified by excising the corresponding gel portion from the gel and then treating with a DNA extraction kit (Sephaglas (trademark) BrandPrep Kit, product of Amersham Pharmacia Biotech), and the purified fragment was cloned into a vector for expression in Escherichia coli using a PCR product direct cloning kit (pT7 BlueT-Vector Kit, product of NOVAGEN) to give pT7-B2DPS. The DNA base sequence was determined by carrying out the reaction on a DNA sequencer (model 377, product of Perkin Elmer) using a DNA sequencing kit (product of Perkin Elmer, ABI PRISM (trademark) BigDye (trademark) Terminator Cycle Sequence Ready Reaction Kit with AmptiTaq (registered trademark) DNA polymerase, FS) and according to the manual attached thereto.

EXAMPLE 4

[0069] The DNA fragment containing the region from the DNA obtained in Example 1 to the 5′-terminal region of the decaprenyl diphosphate synthase gene of Bulleromyces albus IFO 1192 was obtained. Reverse transcription was carried out using a 5′-Full RACE Core Set (product of Takara Shuzo Co., Ltd.), the mRNA prepared in Example 2 as a template, and primer B7ASP (SEQ ID NO:6 in the sequence listing, “5′-terminal region-phosphorylated”), which was generated based on the inner sequence of the DNA fragment obtained in Example 3, to synthesize a cDNA encoding the 5′-terminal region of the gene containing a part of the fragment obtained in Example 3. Then, the cDNA was circularized using the above kit.

[0070] PCR was carried out using this circularized cDNA as a template, and primers B5S (SEQ ID NO:7 in the sequence listing) and B4AS (SEQ ID NO:8 in the sequence listing), which were generated based on the known part of the sequence obtained in Example 3. Furthermore, PCR was carried out to the PCR product using primers B6S (SEQ ID NO:9 in the sequence listing) and B3AS (SEQ ID NO:10 in the sequence listing) to obtain a fragment, about 950 bp in size. The thus-obtained fragment, about 950 bp in size, was purified by excising the corresponding gel portion from the gel and then treating with a DNA extraction kit (Sephaglas (trademark) BrandPrep Kit, product of Amersham Pharmacia Biotech), and the purified fragment was cloned into a vector for expression in Escherichia coli using a PCR product direct cloning kit (pT7 BlueT-Vector Kit, product of NOVAGEN) to give pT7-B3DPS. The DNA base sequence was determined by carrying out the reaction on a DNA sequencer (model 310, product of Perkin Elmer) using a DNA sequencing kit (product of Perkin Elmer, ABI PRISM (trademark) BigDye (trademark) Terminator Cycle Sequence Ready Reaction Kit with AmptiTaq (registered trademark) DNA polymerase, FS) and according to the manual attached thereto.

EXAMPLE 5

[0071] To obtain the full-length sequence of the decaprenyl diphosphate synthase gene of Bulleromyces albus IFO 1192, PCR was carried out using pT7-B2DPS as a template, primer BN1 (SEQ ID NO:11 in the sequence listing), which was generated based on the 5′-terminal sequence of the gene and primer B3AS (SEQ ID NO:10 in the sequence listing) described above to obtain the 5′-terminal region, about 910 bp in size. And, PCR was carried out using pT7-B3DPS as a template, primer B1S (SEQ ID NO:5 in the sequence listing) described above and primer BCH (SEQ ID NO:12 in the sequence listing), which was generated based on the 3′-terminal sequence of the gene, to obtain the 3′-terminal region, about 750 bp in size. The two fragments were mixed and denatured, and then slowly cooled to allow annealing, followed by double-strand synthesis using DNA polymerase. Subsequently, PCR was carried out using the double-stranded DNA as a template, and primers BN1 and BCH to obtain DNA containing the full-length sequence of the gene. The base sequence was determined using a DNA sequencer (model 310, product of Perkin Elmer) and a DNA sequencing kit (product of Perkin Elmer, ABI PRISM (trademark) BigDye (trademark) Terminator Cycle Sequence Ready Reaction Kit with AmptiTaq (registered trademark) DNA polymerase, FS) and according to the manual attached thereto. Thus, the total sequence of the decaprenyl diphosphate synthase gene of Bulleromyces albus IFO 1192 was revealed. Base sequence was determined on the DNA, about 1.6 kbp in size, and the result is shown under SEQ ID NO:1 in the sequence listing. The amino acid sequence deduced from this base sequence is shown under SEQ ID NO:2.

EXAMPLE 6

[0072] The DNA obtained in Example 4 was cleaved with the restriction enzymes NdeI and HindIII, and the cleavage product was inserted into a vector for expression, pUCNT (described in WO 94/03613), to give a decaprenyl diphosphate synthase gene expression vector, pNTB1. The restriction enzyme map of the thus-obtained expression vector pNTB1 is shown in FIG. 1. The symbol DPS stands for the coding region of the decaprenyl diphosphate synthase gene.

EXAMPLE 7

[0073] The decaprenyl diphosphate synthase gene expression vector pNTB1 was introduced into Escherichia coli DH5α to produce recombinant Escherichia coli, E. coli DH5α (pNTB1). The recombinant Escherichia coli was shake-cultured overnight in 10 mL of LB medium at 37° C., and cells were harvested by centrifugation (3,000 revolutions, 20 minutes).

[0074] The cells were suspended in 1 mL of a 3% aqueous solution of sulfuric acid and, after 30 minutes of heat treatment at 120° C., 2 mL of a 14% aqueous solution of sodium hydroxide was added, followed by further 15 minutes of heat treatment at 120° C. To the thus-treated suspension was added 3 mL of hexane-isopropanol (10:2) for effecting extraction. After centrifugation, 1.5 mL of the organic solvent layer was separated, and the solvent was evaporated to dryness under reduced pressure conditions. The residue was dissolved in 200 μL of ethanol, and 20 μL of the solution was analyzed by high-performance liquid chromatography (using LC-10A, product of Shimadzu Corp.). For separation, a reversed phase column (YMC-pack ODS-A, 250×4.6 mm, S-5 μm, 120A) was used, and the coenzyme Q10 formed was detected based on the absorbance at the wavelength 275 nm. An HPLC chart (analysis performed using the mobile phase: ethanol/methanol=2:1) showing production of coenzyme Q10 in the recombinant E. coli DH5α (pNTB1) is shown in FIG. 2. As shown in FIG. 2, it was revealed that, upon introduction of the decaprenyl diphosphate synthase gene for expression thereof, coenzyme Q10, which is originally not produced in Escherichia coli, could now be produced in recombinant Escherichia coli.

[0075] The thus-obtained recombinant Escherichia coli DH5α (pNTB1) has been deposited with the National Institute of Advanced Industrial Science and Technology International Patent Organism Depositary, Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, Japan as of Mar. 16, 2001 (the accession number FERM BP-7512).

INDUSTRIAL APPLICABILITY

[0076] A gene encoding decaprenyl diphosphate synthase, which is the key enzyme in the biosynthesis of coenzyme Q10, was isolated from a fungal species belonging to the genus Bulleromyces and it was sequenced. This could successfully be introduced in Escherichia coli for expression thereof. Furthermore, improvements in gene sequence successfully resulted in production in significant amounts. By using the method of the invention, it becomes possible to efficiently produce coenzyme Q10, which is in use as a drug, among others.

Process for producing coenzyme q10

Information

Publication Number

Date Filed

Date Published

Inventors

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (1)

PCT Information